About us

Molecular targeted radionuclide cancer therapy is becoming of increasing importance, especially for disseminated diseases. Systemic chemotherapies often lack selectivity; targeted radionuclide therapy has important advantages as the radioactive cytotoxic unit of the targeting vector is specifically directed to the cancer, sparing normal tissues.

The basis of this COST Action is the great potential of targeted radionuclide therapy using a variety of vectors and radionuclides.

This Action brings together the different disciplines involved and provide a reliable and rapid means for developing new (fundamental) knowledge, method standardization and products while promoting transfer of technologies.

This Action on cancer therapy using innovative targeting nanomedicines is highly multidisciplinary: nuclear medicine physicians, clinical oncologists, surgeons, physicists, radiobiologists, (in)organic chemists, radiochemists, radiopharmacists, pathologists and scientists from biomics participate in it.

They define innovative new targets for cancer therapy, develop lead compounds and new radiolabelled ligands as vectors, perform molecular imaging and biologic testing, develop improved software and protocols for dosimetric calculations and select new vectors for early human use.

The Action facilitates the cooperation of more than 100 scientists from 21 countries; the economic dimension amounting to about 400 man years.